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Abstract   74 
Evidence shows the quality of reporting of randomised controlled trials (RCTs) is not 75 
optimal. The lack of transparent reporting impedes readers from judging the reliability and 76 
validity of trial findings, prevents researchers from extracting information for systematic 77 
reviews, and results in research waste. The Consolidated Standards of Reporting Trials 78 
(CONSORT) Statement was developed to improve the reporting of RCTs. The primary focus 79 
was on parallel group trials with two treatment groups. Crossover trials are a particular 80 
type of trial for chronic conditions in which participants are randomised to a sequence of 81 
interventions. They are a useful and efficient design because participants act as their own 82 
control. The reporting of crossover trials has, however, been variable and incomplete, 83 
hindering their usefulness in clinical decision making and by future researchers. We 84 
present the CONSORT extension to randomised crossover trials. It aims to facilitate better 85 
reporting of crossover trials. The CONSORT 2010 checklist is revised for crossover designs, 86 
and introduces a modified flowchart and baseline table to enhance transparency. 87 
Examples of good reporting and evidence-based rationale for CONSORT crossover 88 
checklist items are provided. 89 
  90 
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Introduction 91 
Inadequate reporting of randomised controlled trials (RCTs) is associated with bias in the 92 
estimation of treatment effects [1, 2]. It also impairs the critical appraisal of the quality of 93 
randomised trials, which is important to assess the validity of the results of the individual 94 
trial and in conducting systematic reviews. To attempt to address this issue, the 95 
Consolidated Standards of Reporting Trials (CONSORT) statement is a set of 96 
recommendations for the reporting of RCTs [3]. It comprises a checklist of essential items 97 
that should be included in reports of RCTs and a diagram to document the flow of 98 
participants through the trial from before group assignment through to the final analysis. 99 
These items are evidence-based whenever possible. Explanation and elaboration of the 100 
rationale for checklist items is provided in an accompanying article [4]. Many journals now 101 
require that reports of RCTs conform to the recommendations in the CONSORT Statement 102 
[5]. 103 
The primary focus of the CONSORT Statement is the most common type of RCT with two 104 
treatment groups (two ‘arms’) using an individually randomised, parallel group, 105 
superiority design [3]. Almost all the elements of the CONSORT Statement apply equally to 106 
RCTs with other designs, but some elements need adaptation, and in some cases 107 
additional issues need to be discussed. Members of the CONSORT group have published 108 
several extension papers that augment the CONSORT Statement in relation to types of 109 
interventions and data. Extensions of CONSORT 2010 to different trial designs have also 110 
been published including cluster randomised trials [6], non-inferiority and equivalence 111 
trials [7], N-of-1 trials [8], pragmatic trials [9] and within-person trials [10]. As part of that 112 
series, in this paper we extend the CONSORT 2010 recommendations to simple crossover 113 
RCTs in which participants receive two treatments sequentially over two periods and the 114 
order in which treatments are taken is randomised. 115 
Scope of this paper  116 
First, we summarise the key methodological features of crossover trials. Second, we 117 
consider the empirical evidence about how common crossover trials are and review 118 
published studies of the quality of reporting of such trials. Following these literature 119 
reviews, we make suggestions for amendments to the CONSORT checklist adapted for 120 
crossover trials and give illustrative examples of good reporting. In this guideline we focus 121 
on the simplest and most common form of the randomised crossover trial in which all 122 
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participants receive two interventions in one of two sequences (known as the 2x2 or 123 
AB/BA design). Most of the recommendations apply also to the more complicated designs 124 
(more than two interventions, periods or sequences). Specific issues that arise in trials 125 
comparing more than two interventions are briefly discussed in a separate section below.  126 
Methodological features of randomised crossover trials  127 
In contrast to a parallel group trial, each individual in a crossover trial receives multiple 128 
interventions but in a random order, that is participants are randomised to sequences of 129 
interventions.  In this way, each participant acts as his or her own control. Such pre-130 
specified designs should not be confused with trials in which some individuals “cross over” 131 
through non-compliance or use of rescue medication, or in which all participants in the 132 
control group are given the chance to “cross over” to the experimental treatment at the 133 
end of the main trial. Zeng et al found that almost one quarter of records (n=17/72) 134 
labelled as ‘Crossover Assignment’ did not use a randomised crossover design to 135 
randomise participants to a sequence; instead, these trials allowed participants to change 136 
intervention during the course of the trial [11].  137 
Randomised crossover trials present particular challenges. One challenge is the potential 138 
for a ‘carry-over effect’, that is, the effect of the first intervention persists into the second 139 
period such that the observed difference between the treatments depends upon the 140 
order in which they were received. A carry-over effect could have a range of causes. As 141 
well as the obvious problem of a drug or other treatment remaining in the system, 142 
participants’ later responses can be affected by previous side effects or other reactions to 143 
previous treatment. It is recommended that crossover trials should include a sufficient 144 
‘washout’ between the end of the first intervention and the start of the second 145 
intervention, so that any effects from the first intervention will not be ‘carried over’ to the 146 
measurement of outcome in the second intervention period.  147 
Another issue is the ‘period effect’ which occurs when the outcome of interest changes 148 
with time irrespective of treatment effect, for example, the condition may not be stable or 149 
the effect of treatment is seasonal.  150 
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A further issue is the possibility of participants dropping out of the trial if the first 151 
intervention is either very successful or unsuccessful; the results for these participants 152 
cannot be included in the analysis. 153 
Design  154 
The particular strength of the simple AB/BA crossover design is that both interventions are 155 
evaluated on the same participant, allowing comparison at the individual rather than 156 
group level. In addition, participants in a crossover trial can express preferences by 157 
comparing their experiences of the two interventions, which is not possible in a parallel 158 
group design as they will only have received one intervention [12]. 159 
A crucial methodological question is whether the use of the crossover design is justified. 160 
Crossover trials are most appropriate for symptomatic treatment (i.e., treatment for 161 
symptoms such as, for example, pain) of conditions or diseases that are chronic or 162 
relatively stable (such as multiple sclerosis or rheumatoid arthritis), at least over the time 163 
period under study, and when the treatment effects are reversible, and short-lived. The 164 
crossover design is inappropriate when the condition of interest can be cured or when 165 
participants are likely to die over the period of the trial. The design is quite commonly 166 
Period: A length of time where one treatment was received 
Sequence: treatment sequence (AB, BA), subjects allocated to the AB study arm receive 
treatment A first, followed by treatment B, and vice versa in the BA arm 
Within-participant variability: the expected standard deviation of the within-participant 
differences 
Washout: A length of time between treatment periods where no treatment is received in 
order to allow the treatment to wear off 
Carry-over effect: when the effect of the first intervention persists into the second period. 
Period effect: the outcome of interest changes with time irrespective of treatment effect 
Within-participant comparison: A within participant comparison takes into account the 
correlation between measurements for each participant as they act as their own control, 
therefore measurements are not independent. 
 
Box 1: Glossary 
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used, however, in less appropriate circumstances. For example, pregnancy is an intended 167 
outcome of sub-fertility treatment. If a woman becomes pregnant in the first period of the 168 
trial (i.e. before crossover), she will be precluded from entry into subsequent phases of 169 
the trial. Nevertheless the design is defended in the field [13] (for instance it has been 170 
suggested that the pregnancies can be treated statistically as ‘missing at random’ (see 171 
[14])), and remains common despite criticism [15].     172 
The sample size calculation for such trials is based on the within-participant variability in 173 
responses. The crossover design is much more efficient than the parallel design when 174 
there is a high positive correlation between participants’ responses to the different 175 
treatments. Compared to a parallel group design, fewer participants are required for a 176 
crossover trial to obtain the same power for a target effect size and type 1 error rate. 177 
Crossover trials have certain weaknesses. In particular, there can be carry-over effects as 178 
discussed above.  Participants may drop out after the first treatment, and so not receive 179 
the second treatment. Withdrawal may be related to side-effects.  180 
 181 
Analysis  182 
The analysis of a cross-over trial should be based on paired data [16-18]. The estimation 183 
approaches should account for the correlation of repeated measurements in the same 184 
individual. The tests for significance should utilize procedures such as the paired t test 185 
(assuming no carryover/period effect) which is based on within-participant differences for 186 
a continuous response and the Mainland-Gart test for a binary response [19, 20]. 187 
A previously recommended but criticised method of analysing crossover trials was to test 188 
for carryover and if this was significant to discard the second period data and analyse only 189 
the data from the first period. In other words, the first period’s data are analysed as if 190 
from a parallel group trial. Freeman [21] showed that this strategy is seriously flawed, and 191 
leads to biased answers (as is generally the case when the choice between two analyses is 192 
based on the result of a preliminary hypothesis test). Senn [17] and others have argued 193 
that the use of the two period two treatment crossover design is effectively built on the 194 
assumption that there is minimal carryover effect.  195 
The other statistical issue specific to crossover studies is the need for adjustment for 196 
possible period and carryover effects. Parameters can be included for carry-over effect in 197 
CONSORT_Master_Extension_  crossover_20052019_clean.docx                         8 
the statistical model. In the AB/BA crossover design, the terms ‘carry-over’ and ‘treatment 198 
by period’ interaction sometime are used interchangeably because the effects of ‘carry-199 
over’ and ‘treatment by period interaction’ are not separately identifiable in the data. 200 
Although carry-over effect can be estimated, Senn [17] and others have argued that there 201 
is little value of using the carry-over effect to adjust the treatment effect. This is because 202 
such adjustment relies on assumptions about the nature of the possible carry-over effect 203 
and reduces the statistical efficiency for estimating the main treatment effect.  204 
On the other hand, period effect can be dealt with and adjusted for in the analysis. In the 205 
AB/BA crossover design, when equal numbers of participants are allocated to each 206 
sequence, then on average the period effect will not bias the estimate of treatment effect. 207 
However, a period effect will affect the variance estimate because it interferes with how 208 
much of the treatment effect might be attributed to random variation. It is important to 209 
present data for readers to understand the extent of period effect and communicate 210 
clearly whether the period effect was adjusted for or not in the analysis, and whether such 211 
a decision was made a priori. 212 
 213 
How common are randomised crossover trials? 214 
A detailed review of all PubMed-indexed RCTs published in December 2000 found that 215 
74% (383/519) trials used a parallel design and 22% (116/519) were crossover trials [22] 216 
and of the trials indexed in MEDLINE in December 2000, 22% (116/526) were crossover 217 
trials and most used two treatments (72%) and had two periods (64%) [23]. A review of all 218 
PubMed-indexed RCTs published in December 2006 found 77% (477/616) trials used a 219 
parallel design and 16% (100/616) were crossover trials [24]. A review of ClinicalTrials.gov 220 
of intervention studies registered between 2007 and 2010 found that 11.2% (4351/38969) 221 
were of crossover design [25]. A more recent review of PubMed, in December 2012, found 222 
that 8.7% (98/1122) of RCTs were crossover design [26] 223 
What is the quality of reporting of randomised crossover 224 
trials? 225 
Although articles on the quality of reporting of RCTs in relation to CONSORT are relatively 226 
common, few articles have specifically examined the quality of reporting of crossover 227 
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trials. Mills et al. found that randomised crossover trials indexed in MEDLINE in December 228 
2000 frequently omitted details on design, analysis and interpretation [23]. However, 229 
most trials reported and defended a washout period (70%, 87/127) and reported use of 230 
paired data in the analysis (95%, 121/127). Gewandter et al. investigated 124 crossover 231 
clinical trials of pharmacologic treatments for chronic pain published between 1993 and 232 
2013 and found that 28% (35/124) of trials reported baseline and post washout pain levels 233 
and only 32% (23/75) reported a sample size calculation that specifically indicated that it 234 
was based on within participant variability [27]. Straube et al. considered 98 crossover 235 
trials on chronic painful conditions published between 1990 and 2014 and indexed on 236 
PubMed and found that adverse events were poorly reported in the abstracts of the trial 237 
reports and also infrequently reported in the full article and only 23% (23/98) presented a 238 
breakdown by treatment period [28]. Zeng et al [29] found that of 54 phase 3 randomised 239 
crossover trials analysed from ClinicalTrials.gov in September 2014, nearly two-thirds were 240 
a simple AB|BA design with most trials (87%, 47/54) providing sufficient information for 241 
the participant flow throughout the trial. Baseline characteristics were most often 242 
reported for all participants as a single group (59%, 32/54) and primary outcomes and 243 
adverse events were most commonly reported ‘per intervention’ (81%, 44/54 and 83%, 244 
45/54 respectively). The reporting of results in Baseline Characteristics, Outcome 245 
Measures, and Adverse Events generally did not appear to fully reflect the crossover 246 
design. 247 
Several studies have considered the reporting of randomised crossover trials in relation to 248 
meta-analyses [30-32] and found that data were frequently reported inappropriately to 249 
allow them to be included in a meta-analysis. 250 
These studies show that the problems have not improved over many years and the 251 
majority of these studies call for guidance on reporting of randomised crossover trials. 252 
Methods used to develop this CONSORT extension 253 
In May 2002, a number of CONSORT authors met in Arlington, Virginia, USA to consider 254 
extensions to the 2001 CONSORT Statement in a range of different designs.  The first 255 
drafts of a paper extending the Statement to crossover trials were developed by Doug 256 
Altman (DA) and Diana Elbourne in 2002-3.  In 2010, the CONSORT Statement was 257 
updated.   Work on the extension to crossover trials progressed in 2014 when Kerry Dwan 258 
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and then Tianjing Li joined the group. The checklist and explanatory text were informed by 259 
reviews of published randomised trials (as cited above) and completed through numerous 260 
teleconferences between the authors from 2014 to 2018. We followed guidance of the 261 
CONSORT group to include a member of CONSORT Group Executive (DA), who was also 262 
chair of the EQUATOR Steering Group.  A draft paper was distributed to the wider 263 
CONSORT Group and other selected individuals, and the paper was revised to take 264 
account of their feedback, and approved by the Executive.  265 
 266 
CONSORT checklist for randomised crossover RCTs 267 
Table 1 shows the suggested modifications to the Standard CONSORT checklist for 268 
randomised crossover trials. In this section we discuss the checklist items, focussing on 269 
those where there are changes to the standard CONSORT items, explain the background 270 
and provide one or more examples of good reporting. We also discuss some other 271 
checklist items for which we do not suggest any modification but for which 272 
implementation requires specific considerations for crossover RCTs. 273 
Title and Abstract  274 
Item 1a: Title  275 
Identification as a randomised crossover trial in the title.  276 
Standard CONSORT item: Identification as a randomised trial in the title. 277 
Examples 278 
Example 1 279 
“Effect of Ginkgo Biloba on Visual Field and Contrast Sensitivity in Chinese Patients With 280 
Normal Tension Glaucoma: A Randomized, Crossover Clinical Trial” [33]. 281 
 282 
Example 2 283 
 284 
“Effects of Unfermented and Fermented Whole Grain Rye Crisp Breads Served as Part of a 285 
Standardized Breakfast, on Appetite and Postprandial Glucose and Insulin Responses: A 286 
Randomized Cross-over Trial” [34]. 287 
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Explanation  288 
The primary reason for identifying the design in the title is to help readers to identify the 289 
study design. Identification of the trial as a randomised crossover trial also ensures that 290 
readers will start thinking of the implications of the design in relation to sample size and 291 
analysis.  292 
 293 
Item 1b: Abstract  294 
Specify a crossover design and report all information outlined in table 2. 295 
Standard CONSORT item: Structured summary of trial design, methods, results, and 296 
conclusions (for specific guidance see CONSORT for abstracts [3]).  297 
Examples 298 
“CONTEXT:  299 
The relationship between sildenafil citrate use and reported adverse cardiovascular events 300 
in men with coronary artery disease (CAD) is unclear. 301 
OBJECTIVE:  302 
To evaluate the cardiovascular effects of sildenafil during exercise in men with CAD. 303 
DESIGN, SETTING, AND SUBJECTS:  304 
Randomized, double-blind, placebo-controlled two period crossover trial conducted 305 
March to October 2000 at a US ambulatory-care referral center among 105 men (55 to 306 
receive sildenafil first, and 55 to receive placebo first) with a mean (SD) age of 66 (9) 307 
years who had erectile dysfunction and known or highly suspected CAD. 308 
INTERVENTIONS:  309 
All patients underwent 2 symptom-limited supine bicycle echocardiograms separated by 310 
an interval of 1 to 3 days after receiving a single dose of sildenafil (50 or 100 mg) or 311 
placebo 1 hour before each exercise test. 312 
MAIN OUTCOME MEASURES:  313 
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Hemodynamic effects of sildenafil during exercise (onset, extent, and severity of ischemia) 314 
assessed by exercise echocardiography. 315 
RESULTS:  316 
The difference between mean change after sildenafil and placebo use was 4.3 (95% CI, 317 
0.9-7.7; P =.01). Exercise capacity was similar with sildenafil use and placebo use (mean 318 
difference, 0.07; 95% CI, -0.06 to 0.19; P =.29). Exercise blood pressure and heart rate 319 
increments were similar. Dyspnea or angina developed in 69 patients who took sildenafil 320 
and 70 patients who took placebo (P =0.89); exercise electrocardiography was positive in 321 
12 patients (11%) who took sildenafil and 17 patients (16%) who took placebo (P =0.09). 322 
Exercise-induced wall motion abnormalities developed in similar numbers of patients after 323 
sildenafil and placebo use (84 and 86 patients, respectively; P =0.53). Wall motion score 324 
index at peak exercise was similar after sildenafil and placebo use (mean difference, 0.01; 325 
95% CI, -0.01 to 0.03; P =.40). 326 
CONCLUSION:  327 
In men with stable CAD, sildenafil had no effect on symptoms, exercise duration, or 328 
presence or extent of exercise-induced ischemia, as assessed by exercise 329 
echocardiography.” [Adapted from [35]] 330 
Explanation  331 
Clear, transparent, and sufficiently detailed abstracts are important. Readers may only 332 
have access to the abstract, and many others will skim it before deciding whether to read 333 
further. A well-written abstract also helps retrieval of relevant reports from electronic 334 
databases. In 2008 a CONSORT extension on reporting abstracts of randomised trials was 335 
published [36] and those recommendations were incorporated into CONSORT 2010 [3].   336 
Abstracts for crossover RCTs should indicate the design of the trial and therefore the 337 
randomisation to sequence, and analysis taking account of the within-participant 338 
comparisons. Table 2 shows information to be included in the abstract of a crossover trial.    339 
We were not able to find examples of good reporting tackling all the items required. We 340 
have therefore adapted a published abstract (see example).  341 
 342 
CONSORT_Master_Extension_  crossover_20052019_clean.docx                         13 
Methods 343 
Item 3a: Trial design 344 
Rationale for a crossover design. Description of the design features including allocation 345 
ratio, especially the number and duration of periods, duration of washout period and 346 
consideration of carryover effect. 347 
Standard CONSORT item: Description of trial design (such as parallel, factorial) including 348 
allocation ratio 349 
Examples 350 
Example 1 351 
“The trial was a randomised double-blind, placebo controlled, crossover design of 15 352 
months’ duration. …. randomisation (1 month); treatment period one (6 months); 353 
washout (2 months); and finally treatment period two (6 months)… Patients were 354 
randomly assigned azithromycin in treatment period one, followed by placebo in 355 
treatment period two, or placebo in treatment period one followed by azithromycin in 356 
treatment period two.” [37] 357 
Example 2 358 
“A crossover design was chosen for this study instead of the more traditional randomized, 359 
parallel-group design because the within-patient variation is less than the between-360 
patient variation and thus required fewer patients. In addition, some of the known 361 
disadvantages of the crossover design (e.g., larger dropout rate, instability of the patient’s 362 
condition, and a potential carryover effect) were not expected in this study.” [38] 363 
Example 3 364 
“Each treatment period was separated by a 2-week washout, equating to five or more 365 
half-lives for either treatment, to allow the effective systemic elimination of the drug 366 
before initiation of subsequent treatment.” [39] 367 
Example 4 368 
“We did not include a medicine-free period between treatments to increase patient 369 
safety. In addition, we believed the 8-week treatment period was sufficient to allow for 370 
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the washout of the first treatment before the efficacy measurements at the end of period 371 
2.” [40] 372 
Explanation  373 
The methods should contain a rationale for the use of a crossover design in the given 374 
setting. In particular, given that a carry-over effect can neither be identified with sufficient 375 
power, nor can adjustment be made for such an effect in the 2x2 crossover design, the 376 
assumption needs to be made that any carry-over effects are negligible and some 377 
justification presented for this. The description of the design should make clear how many 378 
interventions were tested, through how many periods, including information on the 379 
length of the treatment, run-in and washout periods (if any).  380 
 381 
Item 3b: Changes to methods 382 
Important changes to methods after trial commencement (such as eligibility criteria), with 383 
reasons 384 
No change from standard CONSORT item 385 
 Explanation  386 
A test for carryover is not recommended. However, if a test for carryover is performed as 387 
a result of which the authors use only the first period data, then this should be reported. 388 
The use of the test should also be discussed under item 12a (Statistical methods). The 389 
reason explaining the presence of a carry-over should also be discussed. 390 
 391 
Item 5: Interventions 392 
The interventions with sufficient details to allow replication, including how and when they 393 
were actually administered 394 
Standard CONSORT item: The interventions for each group with sufficient details to allow 395 
replication, including how and when they were actually administered 396 
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Explanation  397 
For this item, ‘for each group’ was deleted for the extension as in a 2x2 randomised 398 
crossover trial, the intention is that all participants receive both of the interventions. 399 
 400 
Item 7a: Sample size 401 
How sample size was determined, accounting for within participant variability 402 
Standard CONSORT item: How sample size was determined 403 
Examples 404 
Example 1 405 
“Earlier research of the Cambridge study site (unpublished data) with the Apathy 406 
Evaluation Scale showed a mean score of 31 points (standard deviation SD=15.6). If we 407 
define a clinical significant improvement on the AES-I as a 35% reduction of the mean 408 
score, this leads to an absolute effect size of 0.35*31 points=10.85 points. Thus a 409 
conservative estimate of 10 units is used for sample size estimation. Furthermore a within 410 
subjects SD=15.0 is assumed. When the sample size in each sequence group is 19, (a total 411 
sample size of 38) a 2 x 2 crossover design will have 80% power to detect a difference in 412 
means of 10.000 (the difference between a Treatment 1 mean, µ1, of 31 and a Treatment 413 
2 mean, µ2, of 21 ) assuming that the crossover ANOVA √MSE is 15.000 (the Standard 414 
deviation of differences, sd, is 21.213) using a two group t-test (Crossover ANOVA) with a 415 
0.050 two-sided significance level. In order to account for potential drop-outs 40 patients 416 
will be randomized. Sample size calculation was performed with nQuery 7.0”  [41] 417 
Explanation  418 
A key advantage of the crossover design is that, for a given significance level, power, and 419 
effect size, a smaller sample size is required compared to a parallel design in which each 420 
participant receives only one treatment. This is because each participant acts as his/her 421 
own control (each participant receives both the experimental and control intervention), so 422 
the within-participant variability is removed.  423 
It is important that trial authors report the usual quantities required for sample size 424 
calculation, including significance level and power, but also for continuous variables the 425 
within-participant variability as shown in Example 1. It is often difficult to get the 426 
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necessary within-participant information to inform the sample size calculation. Published 427 
reports of crossover trials should clarify how the sample size was determined, and ideally 428 
should indicate that an appropriate estimate of within-participant variability was used.  429 
For crossover trials with a continuous outcome, it is the expected standard deviation of 430 
the within-participant differences that must be incorporated into the sample size 431 
estimation. In practice, for many trials it is unlikely that there will be data to support a 432 
realistic estimate of this value, yet ignoring it is likely to result in an overestimation of the 433 
sample size for a crossover trial and is thus conservative [42]. Some attempt should be 434 
made to estimate the standard deviation of the within-participant differences (or allow for 435 
the correlation). 436 
Likewise, with a binary outcome, not considering the paired nature of the data will result 437 
in an unnecessarily large sample size due to failure to account for the within participant 438 
comparison arising from the paired design. Authors are expected give appropriate details 439 
so that the sample size calculation can be replicated.  440 
Any allowance in the sample calculation for losses to follow-up should also be reported.  441 
 442 
Item 8a: Sequence generation 443 
Method used to generate the random allocation sequence. 444 
No change from standard CONSORT item 445 
Examples 446 
Example 1 447 
“After a 4-week placebo run-in, eligible patients were randomly assigned, according to a 448 
computer generated allocation schedule, to 1 of 2 treatment sequences: montelukast and 449 
placebo-matching salmeterol or salmeterol and placebo-matching montelukast. After a 2-450 
week washout, patients crossed over to the other treatment.” [43] 451 
Example 2 452 
“Eligible subjects were randomized in a 1:1 allocation to one of two treatment 453 
sequences—denosumab/alendronate or alendronate/denosumab—and received each 454 
treatment for 1 year.” [44] 455 
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Explanation 456 
In crossover RCTs, allocation sequence refers to the order in which interventions are 457 
received. The allocation may be to sequence one, in which participants have A followed by 458 
B, or to sequence two, in which participants have B followed by A.  459 
 460 
Item 10: Implementation 461 
Who generated the random allocation sequence, who enrolled participants, and who 462 
assigned participants to the sequence of interventions  463 
Standard CONSORT item: Who generated the random allocation sequence, who enrolled 464 
participants, and who assigned participants to interventions 465 
 466 
Explanation  467 
For this item, ‘the sequence of’ was included before interventions as participants are 468 
randomised to a sequence of interventions rather than one intervention. 469 
 470 
Item 12a: Statistical methods 471 
Statistical methods used to compare groups for primary and secondary outcomes which 472 
are appropriate for crossover design (i.e. based on within participant comparison) 473 
Standard CONSORT item: Statistical methods used to compare groups for primary and 474 
secondary outcomes 475 
Examples 476 
Example 1 477 
“Cross-over analyses for health related quality of life scores averaged the between-478 
treatment difference for each patient within each sequence and then across both 479 
sequences, providing an estimate of treatment effect. The estimated treatment 480 
difference, 95% CI and P value were adjusted for period and sequence effects in the 481 
analysis of variance model.” [39] 482 
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Example 2 483 
“A generalized linear mixed-models approach was used to estimate differences between 484 
periods of electrical stimulation and no stimulation while accounting for within-subject 485 
correlations arising from the crossover design.” [45] 486 
Example 3 487 
“Statistical analysis allowed for the comparison of both treatment groups with respect to 488 
baseline information and subsequent comparison at 2 and 4 weeks for treatment effect. 489 
The investigator’s assessment and patient’s assessment of treatment were analysed using 490 
Gart’s test for binary responses, which takes treatment order [strictly period] into 491 
account.” [46] 492 
Example 4 493 
“Side effects and patient preferences were analyzed descriptively and using McNemar’s 494 
test.” [47] 495 
Example 5 496 
“Prescott’s test was used to analyze the primary end point to test the significance of 497 
difference between the two treatments in the presence of period effects.” [39] 498 
Explanation 499 
In line with recommendations made by the International Committee for Medical Journal 500 
Editors (ICMJE) and the CONSORT group, analytical methods should be described “with 501 
enough detail to enable a knowledgeable reader with access to the original data to verify 502 
the reported results.”(http://www.icmje.org/recommendations/browse/manuscript-503 
preparation/preparing-for-submission.html#d, accessed March 2019) Identification of the 504 
crossover design and the statistical methods used allows readers to evaluate the methods 505 
of analysis.  506 
The analysis of a crossover trial should respect the within-participant nature of the 507 
comparisons. The Methods section should specify which method of analysis was used. This 508 
should make clear how the within-participant analysis has been constructed, for example 509 
using t tests on within-participant differences, or ANOVA with participant, period and 510 
treatment effects. If period effects and carryover have been modeled then this should be 511 
reported. Likewise, for a binary outcome, conditional logistic regression provides an 512 
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alternative way of conducting the Mainland-Gart test. The consequences of an analysis 513 
not accounting for a within-participant comparison may overestimate the variance for the 514 
treatment effect.  515 
In some crossover trials participants are measured on the outcome variable at the 516 
beginning as well as at the end of both periods, and the treatment effect is estimated 517 
using the change score from each period. This seemingly intuitive approach is claimed to 518 
eliminate carryover effect; however it could produce a less precise and even biased 519 
estimate of treatment effect [48, 49] and therefore should be discouraged. 520 
While missing data raise the same generic issues in crossover trials as in other designs, the 521 
specifics are more complicated. The analysis model, in the absence of missing data, should 522 
be identified and the role of baseline data needs to be carefully considered, since often 523 
baseline adjustment increases the standard error.  A mixed model of all available data 524 
(e.g. in this context, with a mixture of fixed and random effects) is typically the preferred 525 
first step, with the contextually appropriate adjustment for within-subject dependence, 526 
and is valid under Rubin’s ‘Missing at Random’ assumption. Broadly, this states that the 527 
distribution of later outcome data, given treatment sequence and earlier data, is the same 528 
whether or not those data are observed. Analysis of the complete records gives a valid ITT 529 
estimate assuming the distribution of the outcomes given baseline and treatment 530 
sequence is the same, whether or not they are observed (i.e. missing at random). One can 531 
explore the robustness of the conclusion to this untestable assumption by multiply 532 
imputing the data and forcing the distribution of imputed outcomes to differ from the 533 
observed ones given baseline and treatment sequence. The use of multiple imputation, 534 
imputing from subsets of patients (rather than single mean imputation, last value carried 535 
forward, or best/worst imputation) is welcome because the imputed data is both 536 
contextually plausible and appropriately reflects the variability  [50]. 537 
 538 
Results 539 
Item 13a: Participant flow (A flow diagram is strongly recommended) 540 
The numbers of participants who were randomly assigned, received intended treatment, 541 
and were analysed for the primary outcome, separately for each sequence and period. 542 
[See Figure 1] 543 
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Standard CONSORT item: For each group, the numbers of participants who were randomly 544 
assigned, received intended treatment, and were analysed for the primary outcome 545 
Examples 546 
Example 1: [51] 547 
 548 
 549 
 550 
 551 
  552 
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Example 2: [52] 553 
 554 
Explanation 555 
The flow diagram is a key element of the CONSORT Statement and has been widely 556 
adopted. For crossover trials it is important to understand the flow of participants across 557 
periods. Although we recommend a flow diagram for communicating the flow of 558 
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participants throughout the study, the exact form and content can vary in relation to the 559 
specific features of a trial. We recommend using vertical alignment and including a 560 
timescale.    561 
 562 
Item 13b: Losses and exclusions 563 
Number of participants excluded at each stage, with reasons, separately for each 564 
sequence and period.   565 
Standard CONSORT item: For each group, losses and exclusions after randomisation, 566 
together with reasons 567 
Examples 568 
Example 1  569 
“One subject assigned to receive active placebo first withdrew because of a scheduling 570 
conflict before taking any study medication. Two subjects assigned to receive pregabalin 571 
first withdrew in the first period because of adverse events. The remaining 26 subjects 572 
completed the study.” [53] 573 
Example 2 574 
“Of the 23 patients who provided consent, 17 were randomized to a treatment sequence 575 
(9 to pancrelipase then placebo, 8 to placebo then pancrelipase). Sixteen patients 576 
completed the study; 1 patient (pancrelipase/ placebo sequence) withdrew consent on 577 
day 2 of the first treatment period.” [54] 578 
Explanation 579 
A participant who drops out part way through the trial will have their outcome assessed 580 
for only one intervention. Dropping out maybe informative; for example, they may be 581 
dissatisfied with treatment they were given so do not wish to try any other treatments. 582 
This may bias the results.  583 
Authors should indicate the loss of participants for each intervention, separately for each 584 
sequence and period, possibly within the flow diagram with reasons if possible.  585 
There are statistical methods to deal with incomplete data (see Item 12a). 586 
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Item 15: Baseline data 587 
A table showing baseline demographic and clinical characteristics by sequence and period. 588 
Standard CONSORT item: a table showing baseline demographic and clinical characteristics 589 
for each group 590 
Examples 591 
Example 1: By sequence only [43] 592 
Characteristic Montelukast-salmeterol (n=78) Salmeterol-montelukast (n=76) 
Sex, No (%) 
Male 
Female 
 
43 (55.1) 
35 (44.9) 
 
46 (60.5) 
30 (39.5) 
Race, No. (%) 
Asian 
Black 
White 
Other 
 
1 (1.3) 
11 (4.1) 
38 (48.7) 
28 (35.9) 
 
0 (0.0) 
7 (9.2) 
41 (53.9) 
28 (36.8) 
Age, mean (SD), y 10.2 (2.0) 9.8 (2.0) 
Preexercise FEV1, mean (SD), L 2.30 (1.1) 2.2 (0.6) 
Preexercise FEV1, mean (SD), % 
predicted 
96.3 (31.8) 92.8 (12.4) 
Maximum percentage decrease 
in FEV1 after exercise, mean (SD) 
24.8 (10.3) 25.4 ( 9.0) 
AUC0–20min, mean (SD), %·min 320.1 (208.6) 317.7 (165.7) 
Time to recovery, mean (SD), min 23.5 (10.5) 21.5 ( 8.3) 
Maximum FEV1, mean (SD), % 
predicted 
99.9 (32.5) 100.5 (15.6) 
Average percentage change in 
FEV1 after first SABA use, mean 
(SD) 
1.4 (11.0) 4.8 (10.9) 
Need for rescue medication after 
challenge, No. (%) 
No 
Yes 
 
 
77 (98.7) 
1 (1.3) 
 
 
75 (98.7) 
1 (1.3) 
Asthma exacerbations limit 
normal physical activity, No. (%) 
Not at all 
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Slightly 
Moderately 
Severely 
2 (2.6) 
21 (26.9) 
46 (59.0) 
9 (11.5) 
4 (5.3) 
20 (26.3) 
44 (57.9) 
8 (10.5) 
Abbreviations: AUC0–20min, area under the curve for the first 20 minutes after exercise; FEV1, forced expiratory volume in 1 second; 593 
SABA, short-acting β-agonist. 594 
a Based on the number of patients who returned to within 5% of the baseline FEV1 value. 595 
 596 
Example 2: By sequence and by total (Adapted from [55]) 597 
Characteristic Treatment sequence 
100 IU kg-1 once weekly 
to 50 IU kg-1 twice 
weekly 
(n = 22) 
50 IU kg-1 twice weekly 
to 100 IU kg-1 once 
weekly 
(n = 25) 
Total 
(N = 50)* 
Mean age, years (SD) 31.7 (13.4)  25.1 (14.4)  27.7 (13.9) 
Sex, n (%) 
Male 
 
22 (100.0) 
 
25 (100.0) 
 
50 (100.0) 
Ethnicity, n (%) 
White 
Black 
Hispanic or Latino 
Non-Hispanic or non-
Latino 
 
21 (95.5) 
1 (4.5) 
5 (22.7) 
17 (77.3) 
 
25 (100.0) 
0 
2 (8.0) 
23 (92.0) 
 
49 (98.0) 
1 (2.0) 
7 (14.0) 
43 (86.0) 
Mean weight, kg (SD) 72.3 (14.2) 64.6 (26.0) 69.2 (21.3) 
Target joints†, n (%) 20 (90.9) 19 (76.0) 42 (84.0) 
Haemophilic 
arthropathy†, n (%) 
20 (90.9) 17 (68.0) 40 (80.0) 
Decreased movement 
due to haemophilic 
arthropathy†, n (%) 
18 (81.8) 14 (56.0) 34 (68.0) 
 
*Includes three subjects who received study drug in first on-demand period, but were not randomized. 598 
†At study entry. 599 
SD, standard deviation. 600 
 601 
Explanation  602 
Random assignment by individual ensures that any differences in group characteristics at 603 
baseline are the result of chance rather than some systematic bias [2]. For randomised 604 
crossover trials, it is desirable to know that baseline characteristics that can be affected by 605 
the intervention return to their initial state at the beginning of the second period. The by-606 
sequence information is needed to assess whether randomisation has achieved balance 607 
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between the sequences for important variables at the start of the trial. The by-period 608 
information is helpful for readers to understand whether the treatment effect in the next 609 
period is confounded by the changing participant characteristics between periods. 610 
Characteristics that remain the same at the start of the two periods such as sex, age, for 611 
example, can be presented once; however, unstable prognostic factors and baseline value 612 
of the main outcome must be checked at beginning of each period. If the characteristic 613 
can change over time, then a baseline table by sequence only precludes inference of 614 
differences between period (i.e. treatment). 615 
 616 
Item 16: Numbers analysed  617 
Number of participants (denominator) included in each analysis and whether the analysis 618 
was by original assigned groups. 619 
Standard CONSORT item:  For each group, number of participants (denominator) included 620 
in each analysis and whether the analysis was by original assigned groups. 621 
 622 
Explanation 623 
The number of participants who contribute to the analysis of a trial is essential to 624 
interpreting the results. The analysis of crossover trials has to account for the paired 625 
nature of the design, the numbers analysed for each outcome should be equal to the 626 
numbers of within-participant differences or contrasts that were possible. However, not 627 
all participants may contribute to the analysis of each outcome. In a crossover trial when 628 
participants do not contribute to the analysis from one period the corresponding period 629 
may be lost. Assuming no carryover or period effect, if imputation is undertaken the data 630 
could be salvaged and when no imputation is undertaken the data is lost and becomes a 631 
power issue.  As the sample size calculation and hence the power of the study is 632 
calculated on the assumption that all participants will provide information, the number of 633 
participants contributing to a particular analysis should be reported so that any potential 634 
drop in statistical power can be assessed. When there is carryover/period effect, missing 635 
data will result in a biased estimate. In addition, and as explained in detail in the CONSORT 636 
2010 guideline [2], it should be specified whether a per-protocol or an Intention-to-treat 637 
analysis was followed. 638 
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  639 
Item 17a: Outcomes and estimation 640 
For each primary and secondary outcome, results, including estimated effect size and its 641 
precision (such as 95% confidence interval) should be based on within participant 642 
comparisons. In addition, results for each intervention in each period are recommended. 643 
Standard CONSORT item: For each primary and secondary outcome, results for each 644 
group, and estimated effect size and its precision (such as 95% confidence interval) 645 
Examples 646 
Example 1: Coefficient of fat absorption (CFA) results, by treatment and severity of 647 
exocrine pancreatic insufficiency (EPI) [54] 648 
Variable Pancrelipase 
(n=16) 
Placebo (n=16) Treatment 
Difference 
(Pancrelipase-
Placebo) (n=16) 
P 
CFA, % 
LS mean (SE) 
95% CI 
 
82.8 (2.7) 
77.0-88.6 
 
47.4 (2.7) 
41.6-53.2 
 
35.4 (3.8) 
27.2-43.6 
 
<0.001 
- 
CFA by severity of EPI, % 
Placebo CFA <=50% 
LS mean (SE) 
95% CI 
 
n=10 
81.8 (1.7) 
77.9-85.7 
 
n=10 
37.3 (1.7) 
33.4-41.2 
 
n=10 
44.5 (2.4) 
39.0-50.0 
 
 
<0.001 
- 
Placebo CFA >50% 
LS mean (SE) 
95% CI 
n=6 
84.5 (2.9) 
76.5-92.5 
n=6 
64.3 (2.9) 
55.3-72.3 
n=6 
20.2 (4.1) 
8.9-31.6 
 
0.008 
- 
 649 
 650 
Example 2: treatment comparisons and changes between baseline and treatment 651 
endpoint for secondary outcomes (Adapted from [38]) 652 
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Secondary 
outcome 
Changes between baseline to end point 
Mean (SE) 
Treatment comparisons 
Treatment Sildenafil 
PRN 
Tadalafil 
OaD 
Tadalafil 
PRN 
LS mean difference (SE) [95% CI. P value] 
Tadalafil 
OaD- 
Sildenafil 
PRN 
Tadalafil 
OaD- 
Tadalafil 
PRN 
Tadalafil 
PRN- 
Sildenafil 
PRN 
SEAR Scale 
 
 
Sexual 
relationship 
Confidence 
 
Total 
25.40 (1.36) 
N = 347 
 
19.50 (1.31) 
N = 347 
 
 
22.87 (1.29) 
N = 347 
25.56 (1.36) 
N = 348 
 
19.40 (1.31) 
N = 349 
 
 
22.94 (1.29) 
N = 348 
26.92 (1.35) 
N = 355 
 
20.42 (1.30) 
N = 355 
 
 
24.13 (1.29) 
N = 355 
0.23 (1.11)  
[-1.95, 2.42; 
P = 0.834] 
-0.07 (1.07) 
[-2.17, 2.04; 
P = 0.951] 
0.11 (1.050 
[-1.95, 2.17; 
P = 0.915] 
-1.47 (1.11)  
[-3.65, 0.70; 
P = 0.185] 
-1.12 (1.06) 
[-3.22, 0.97; 
P = 0.291] 
 
-1.30 (1.040 
[-3.35, 0.74; 
P = 0.212] 
1.71 (1.10)  
[-0.46, 3.87; 
P = 0.123] 
1.06 (1.06)  
[-1.03, 3.15; 
P = 0.320] 
 
1.42 (1.04)  
[-0.63, 3.46; 
P = 0.174] 
IIEF-EF 
Domain 
Score 
9.70 (0.36) 
N = 348 
 
8.68 (0.36) 
N = 350 
9.54 (0.36) 
N = 355 
-0.85 (0.30) 
[-1.43, -0.27; 
P = 0.004] 
-0.80 (0.29) 
[-1.37, -0.22; 
P = 0.007] 
-0.05 (0.29) 
[-0.62, 0.53; 
P = 0.866] 
EDITS Score 75.68 (1.32) 
N = 348 
75.81 (1.31) 
N = 351 
79.50 (1.31) 
N = 355 
0.12 (1.28) [-
2.40, 2.64; 
P = 0.926] 
-3.55 (1.27) 
[-6.05, -1.04; 
P = 0.006] 
3.66 (1.27) 
[1.16, 6.17; 
P = 0.004] 
Morning 
erection 
frequency 
0.11 (0.02) 
N = 347 
0.26 (0.02) 
N = 352 
0.20 (0.02) 
N = 355 
0.15 (0.01) 
[0.12, 0.18; 
P < 0.001] 
0.06 (0.01) 
[0.03, 0.09; 
P < 0.001] 
0.09 (0.01) 
[0.06, 0.12; 
P < 0.001] 
 653 
Example 3 654 
“Eighty patients (70%) preferred pazopanib; the most common reasons included better 655 
overall quality of life (QoL) and less fatigue. Twenty-five patients (22%) preferred sunitinib; 656 
the most common reasons included less diarrhoea and better overall QoL. Physician 657 
preferences were consistent with patient preferences. More physicians preferred to 658 
continue their patients on pazopanib (61%) than on sunitinib (22%), with 17% stating no 659 
preference.” [39] 660 
 661 
CONSORT_Master_Extension_  crossover_20052019_clean.docx                         28 
Example 4: Incidence Rate Ratios (IRR) with 95% confidence intervals for effects of 662 
treatment, time and treatment-time interaction on behaviour and affect scores after 663 
taking account of age, gender and dementia severity [56] 664 
 Behaviour 
 
Affect 
 
 Positive Negative 
IRR p 
value 
IRR p 
value 
IRR p 
value 
Treatment Lavender compared to 
control 
0.884 
(0.778-
1.004) 
0.057 
 
1.072 
(0.848-
1.355) 
0.56 
 
0.891 
(0.504-
1.573) 
0.690 
 
Time First 30 minutes post-
exposure compared to 
pre- exposure 
0.899 
(0.793-
1.020) 
0.097 
 
0.900 
(0.706-
1.147) 
0.393 
 
0.960 
(0.550-
1.675) 
0.887 
 
Second 30 minutes 
post-exposure 
compared to pre- 
exposure 
0.858 
(0.755-
0.974) 
0.018 
 
0.865 
(0.678-
1.106) 
0.248 
 
0.641 
(0.348-
1.179) 
0.153 
 
Treatment- 
time 
interactions 
Lavender x first 30 
min post-exposure 
0.961 
(0.798-
1.157) 
0.672 
 
1.020 
(0.726-
1.433) 
0.910 
 
0.848 
(0.371-
1.938) 
0.696 
 
 Lavender x second 30 
min post-exposure 
1.045 
(0.869-
1.259) 
0.636 
 
0.954 
(0.675-
1.348) 
0.790 
 
0.687 
(0.269-
1.750) 
0.431 
 
 665 
 666 
Explanation  667 
When reporting the results of randomised crossover trials, point estimates with 668 
confidence intervals should be reported for primary and secondary outcomes; this is the 669 
same as the standard CONSORT guideline except that these results should be based on the 670 
appropriate within-participant analysis. Results should not be presented as though from a 671 
parallel group trial or by double counting the participants. Ideally, as the correlation 672 
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impacts on the power of the study, the correlation coefficient for each primary outcome 673 
being analysed should also be provided to help with the planning of future crossover 674 
trials.  675 
For binary outcomes a presentation using a matched tabulation format is desirable as it 676 
allows the reader to see the concordant and discordant pairs.  The matched tabulation 677 
facilitates the use of such trials in future meta-analyses as it allows using appropriate 678 
formulas to adjust the between treatment variance downwards by accounting for the 679 
within-participant correlation, even when not available [57-59]. Presentation of the 2x2 680 
table of results from a crossover design in a parallel trial format does not allow for 681 
appropriate adjustments of the between treatment variance [57]. The paired presentation 682 
is also helpful for future sample size calculations. However, in many circumstances the 683 
data will be analysed by a model accounting for the design and displayed as shown in 684 
example 4. 685 
Presentation of the results for each intervention in each period is recommended because 686 
these can be used for understanding any treatment by period interaction, regardless of 687 
how the trial investigators handled it in their analysis (see Table 7 of Li 2015 [31]). 688 
Ideally, participant preference outcomes should also be reported at the participant level. 689 
For example the participants should be split into those who prefer intervention A and 690 
those who prefer B and analysed using McNemar’s test or, if allowing for period, the 691 
Mainland-Gart test or Prescott’s test. 692 
 693 
Item 19: Harms  694 
Describe all important harms or unintended effects in a way that accounts for the design 695 
(for specific guidance see CONSORT for harms [60]).  696 
Standard CONSORT item: All important harms or unintended effects in each group (for 697 
specific guidance see CONSORT for harms [60]) 698 
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Examples (this example is fictional) 699 
  Number of 
adverse 
events 
Vomiting No adverse event under either NSAIDS or placebo  
No adverse event under NSAIDS but adverse events observed 
under placebo 
Adverse event observed under NSAIDS but not under placebo 
Adverse events observed under both NSAIDS and placebo 
108 
7 
 
13 
3 
 700 
Explanation 701 
In addition to describing the types of adverse events and the overall frequency under each 702 
intervention, for crossover trials, presenting concordant and discordant pairs of adverse 703 
events or providing estimates of effect and precision (when between group comparisons 704 
were made) will inform the relative safety of the interventions tested. The table above 705 
provides an example of how to tabulate adverse events. 706 
 707 
Discussion  708 
Item 20: Limitations 709 
Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 710 
multiplicity of analyses. Consider potential carry-over effects 711 
Standard CONSORT item: Trial limitations, addressing sources of potential bias, 712 
imprecision, and, if relevant, multiplicity of analyses 713 
Examples 714 
Example 1  715 
“The 24-hour washout period may have been insufficient to eliminate the effects of 716 
stimulation. Potential carryover effects should be addressed by the use of alternative 717 
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study designs (eg, parallel groups, longer study/washout periods, stepped-wedge 718 
designs).” [45] 719 
Example 2 720 
“Strengths of this study include blinding of study treatments and a cross-over design, 721 
where patients were exposed to both treatments in similar health states. This allowed for 722 
detection of differences in tolerability not confounded by differences in health states and 723 
for each patient to act as their own control. In addition, the 2-week washout period and 724 
random assignment minimized possible effects of the order of treatment and carryover.” 725 
[39] 726 
Example 3 727 
“Finally, it is possible that the crossover design could have obscured differences in the 728 
period on and off HCQ. While allowing for a washout period may have helped rule out 729 
such a possibility, the pilot study suggested no such washout period was required.” [61] 730 
Explanation 731 
A limitation with the crossover design is that the treatment from the first period may 732 
affect the results from the second period, either to improve the outcome with the 733 
opposite treatment or to suppress the effect. This carry-over effect could potentially 734 
render a crossover trial invalid and reporting of such a limitation is unlikely to be found 735 
given that it would invalidate the trial results.  Possible limitations that should be reported 736 
include losses to follow-up before the second intervention is applied and mixing up of the 737 
interventions such that the sequence which was applied was not that to which the 738 
participant was randomised. The appropriateness of a cross-over design in terms of the 739 
stability of the disease over the duration of the trial could also be discussed. 740 
 741 
 742 
More complicated trial designs 743 
In the previous sections we discussed reporting of the simple 2x2 design in which each 744 
participant is randomised to one of two sequences in which to receive the two competing 745 
interventions. More complicated variations of the crossover design include: comparing 746 
three or more interventions (please see the CONSORT extension for multi-arm trials [62]) 747 
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and cluster crossover randomised trials. In a cluster crossover randomised controlled trial, 748 
each cluster receives multiple interventions in a randomised sequence [63]. A recent 749 
review found that there is a need to ensure an appropriate analysis is undertaken and 750 
reporting needs to be improved [64]. The development of an extension of CONSORT to 751 
cluster crossover trials is underway (Joanne McKenzie, personal communication). 752 
There also may be issues of repeated measurements (i.e. measurements taken at several 753 
timepoints) or multiplicity within participants in crossover trials (i.e. both eyes are 754 
assessed within participants). Other, less frequently used versions of the crossover design 755 
include: Bioequivalence studies, Balaam’s design, extra period designs, n-of-1 designs and 756 
an incomplete block design [17].  757 
 758 
Comment 759 
Reports of randomised controlled trials should include key information on the methods 760 
and findings to allow readers to accurately interpret the results. This information is 761 
particularly important for meta-analysts attempting to extract data from such reports. The 762 
CONSORT 2010 statement provides the latest recommendations from the CONSORT 763 
Group on essential items to be included in the report of a randomised controlled trial. In 764 
this paper we introduce and explain corresponding updates in an extension of the 765 
CONSORT checklist specific to reporting randomised crossover trials. 766 
Use of the CONSORT statement for the reporting of two group parallel trials is associated 767 
with improved reporting quality [65]. We believe that the routine use of this proposed 768 
extension to the CONSORT statement will eventually result in improvements to crossover 769 
designs. When reporting a randomised crossover trial, authors should address all 25 items 770 
on the CONSORT checklist using this document in conjunction with the main CONSORT 771 
guidelines [3]. Authors may also find it useful to consult the CONSORT extensions for other 772 
trial designs which are available at http://www.consort-statement.org/extensions.  773 
The CONSORT statement can help researchers designing trials in the future and can guide 774 
peer reviewers and editors in their evaluation of manuscripts. Many journals recommend 775 
adherence to the CONSORT recommendations in their instructions to authors. We 776 
encourage them to direct authors to this and to other extensions of CONSORT for specific 777 
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trial designs. The most up to date versions of all CONSORT recommendations can be found 778 
at www.consort-statement.org.  779 
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